Kulkarni P S, DeSantis L
Department of Ophthalmology and Visual Science, School of Medicine at University of Louisville, Louisville, Kentucky 40202, USA.
J Glaucoma. 2001 Oct;10(5):423-6. doi: 10.1097/00061198-200110000-00011.
RS-Betaxolol (equimolar R- and S- isomers) lowers intraocular pressure and dilates precontracted retinal and posterior ciliary arteries in vitro. Betaxolol's vasorelaxant effect is thought to involve the inhibition of calcium influx into vascular smooth muscle and is unrelated to its stereoselective beta-adrenergic blocking action. The authors assessed the vasodilatory effect of RS-betaxolol on different diameters of bovine retinal arterioles and venules, and these responses were compared with the responses induced by R- and S-betaxolol isomers in vitro.
In-vitro preparations of the bovine retinal microcirculatory system were perfused continuously with oxygenated, heparinized physiological salt solution at 37 degrees C. Diameters of retinal arterioles and venules were measured using video imaging. The retinal vessels were preconstricted with 40 mM KCl, and concentration-response curves for vasodilation were obtained for RS-betaxolol, R-betaxolol, and S-betaxolol.
Baseline diameters of first-order (A1) and second-order (A2) branches of retinal arterioles were 50 +/- 0.6 microm and 39 +/- 1 microm, respectively (n = 20), whereas diameters of first-order (V1) and second-order (V2) branches of venules were 75 +/- 0.8 microm and 50 +/- 0.4 mM, respectively (n = 20). The diameters of all sizes of retinal arterioles and venules were significantly reduced (i.e., vasoconstricted) in the presence of 40 mM KCl (n = 20). These preconstricted vessels were relaxed in a dose-dependent manner by cumulative additions of RS-betaxolol, R-betaxolol, and S-betaxolol. The dose-response curves of these compounds were not significantly different.
RS-Betaxolol, R-betaxolol, and S-betaxolol were equiactive and produced concentration-dependent vasodilatation of all sizes of retinal arterioles and venules studied.
RS-倍他洛尔(等摩尔的R-和S-异构体)可降低眼压,并在体外使预收缩的视网膜动脉和睫状后动脉扩张。倍他洛尔的血管舒张作用被认为涉及抑制钙流入血管平滑肌,且与其立体选择性β-肾上腺素能阻断作用无关。作者评估了RS-倍他洛尔对不同直径的牛视网膜小动脉和小静脉的舒张作用,并将这些反应与R-和S-倍他洛尔异构体在体外诱导的反应进行比较。
在37℃下,用含氧、肝素化的生理盐溶液连续灌注牛视网膜微循环系统的体外制剂。使用视频成像测量视网膜小动脉和小静脉的直径。视网膜血管用40 mM氯化钾进行预收缩,然后获得RS-倍他洛尔、R-倍他洛尔和S-倍他洛尔的血管舒张浓度-反应曲线。
视网膜小动脉一级(A1)和二级(A2)分支的基线直径分别为50±0.6微米和39±1微米(n = 20),而小静脉一级(V1)和二级(V2)分支的直径分别为75±0.8微米和50±0.4毫米(n = 20)。在40 mM氯化钾存在下,所有大小的视网膜小动脉和小静脉直径均显著减小(即血管收缩)(n = 20)。通过累积添加RS-倍他洛尔、R-倍他洛尔和S-倍他洛尔,这些预收缩的血管以剂量依赖性方式舒张。这些化合物的剂量-反应曲线无显著差异。
RS-倍他洛尔、R-倍他洛尔和S-倍他洛尔具有同等活性,并对所研究的所有大小的视网膜小动脉和小静脉产生浓度依赖性血管舒张作用。